immunotherapy and triple negative breast cancer

Release time ：Nov-15,2024

Immunotherapy offers a novel therapeutic approach for treating triple-negative breast cancer, a subtype that is less responsive to traditional endocrine and targeted therapies due to the absence of estrogen receptors, progesterone receptors, and HER2 protein expression. Consequently, immunotherapy has emerged as a significant area of research.

Immunotherapy leverages the patient’s immune system to identify and combat cancer cells. Notably, immune checkpoint inhibitors are extensively studied, as they can disrupt the signaling pathways between cancer cells and immune cells, enhancing the latter’s ability to detect and destroy cancer cells. Beyond immune checkpoint inhibitors, other immunotherapeutic strategies, including CAR-T cell therapy and tumor vaccines, are also under investigation.

For patients afflicted with triple-negative breast cancer, immunotherapy presents a promising treatment option. However, it is crucial to recognize that immunotherapy is not universally applicable and may induce adverse effects. Patients contemplating immunotherapy should do so under the supervision of a physician, vigilantly monitor their physical responses to facilitate timely adjustments to the treatment regimen. Additionally, maintaining healthy lifestyle practices, such as a balanced diet and regular exercise, can enhance therapeutic outcomes and overall quality of life.